Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

May 28, 2025

Immunic, Inc. Announces Proposed Public Offering
May 2, 2025

Immunic to Participate in Scientific and Industry Conferences in May
April 30, 2025

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
April 10, 2025

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
April 9, 2025

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
April 1, 2025

Immunic, Inc. to Participate in Scientific and Industry Conferences in April
March 3, 2025

Immunic to Participate in Scientific and Investor Conferences in March
February 26, 2025

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
February 20, 2025

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
February 4, 2025

Immunic to Participate in Investor and Scientific Conferences in February

Show per page